Abstract
Tumour necrosis factor inhibitors have revolutionised the management of Crohn's disease, but reports of a possible association between concomitant infliximab and immunomodulator therapy and hepatosplenic T-cell lymphoma (a rare form of aggressive non-Hodgkin's lymphoma) have emerged. We describe the first case in Australia of hepatosplenic T-cell lymphoma in a patient who had been treated with infliximab and immunomodulators for Crohn's disease.
MeSH terms
-
Adult
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / therapeutic use
-
Crohn Disease / drug therapy
-
Fatal Outcome
-
Humans
-
Immunologic Factors / adverse effects
-
Immunologic Factors / therapeutic use
-
Infliximab
-
Liver Neoplasms / chemically induced*
-
Lymphoma, T-Cell / chemically induced*
-
Male
-
Splenic Neoplasms / chemically induced*
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Antibodies, Monoclonal
-
Immunologic Factors
-
Tumor Necrosis Factor-alpha
-
Infliximab